Drug Profile
Research programme: anti-VEGF therapeutics - Ocular Therapeutix
Alternative Names: Bevacizumab sustained-release intravitreal depot - Ocular Therapeutix; Sustained release anti-VEGF drug depots - Ocular TherapeutixLatest Information Update: 28 Jun 2019
Price :
$50
*
At a glance
- Originator Ocular Therapeutix
- Class Monoclonal antibodies
- Mechanism of Action Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Wet age-related macular degeneration
Most Recent Events
- 28 Jun 2019 No recent reports of development identified for preclinical development in Wet age-related macular degeneration in USA (Intravitreous, Injection)
- 01 May 2015 Preclinical trials in Wet age-related macular degeneration in USA (Intravitreous)